B&L launches Stellaris Vision Enhancement System - Ophthalmology Times Europe

ADVERTISEMENT

CATARACT

GLAUCOMA

REFRACTIVE

RETINA

Tweet!
B&L launches Stellaris Vision Enhancement System

Ophthalmology Times Europe Meeting E-News

Bausch & Lomb (B&L) today launched its new Stellaris Vision Enhancement system, further demonstrating its dedication to its microincision cataract surgery franchise.

Following on from the successes of the Millennium Microsurgical System and the Akreos acrylic intraocular lenses (IOLs), Stellaris offers surgeons the opportunity to perform both biaxial and coaxial microincision cataract surgery (B-MICS and C-MICS, respectively) procedures through a 1.8 mm incision.

According to the firm, the Stellaris EQ fluidics management technology allows surgeons to choose either a flow-vacuum module (AFM) or an advanced vacuum module (AVM). It also allows them to switch between the two for greater flexibility, stability and efficiency.

Additional features include the new ergonomically-designed, six-crystal phaco handpiece, Bluetooth wireless-enabled dual-linear foot pedal, and high-definition touch-screen display.

"With the launch of the Stellaris Vision Enhancement System and our Akreos MI60 microincision lens, we are poised to further enhance our leadership position," said Alan Farnsworth, B&L corporate senior vice president and president, Europe, Middle East and Africa Region.

According to H. Burkhard Dick, MD of Universitäts-Augenklinik, Center for Vision Science, Ruhr University, Germany, who has used the Stellaris system in more than 50 cases, it offers good performance, control and versatility. Meanwhile, he feels the optimized cutting deals with even the hardest nuclei whilst the improved fluidics contribute greatly to chamber stability when performing both biaxial and microcoaxial phaco.

On a scale of 1 to 10, with 1 being the lowest and 10 being the highest, how would you rate this article?
Your original vote has been tallied and is included in the ratings results.
View our top pages
Average rating for this page is: 2.67
WHAT DO YOU THINK?

AddThis Social Bookmark Button

Rate this article
Your comments
Discuss on our forum
Follow us on Twitter

 

Survey
What do you believe is the most appropriate glaucoma therapy option?
Monotherapy
Multiple therapies
Fixed-dose combinations
Various/individualized treatment
Monotherapy
29%
Multiple therapies
0%
Fixed-dose combinations
24%
Various/individualized treatment
47%
View Results
Source: Ophthalmology Times Europe Meeting E-News,
Click here